

Fluoroquinolone-Associated Tendinopathy: A Critical Review of the Literature

Yasmin Khaliq¹ and George G. Zhanel²

¹Department of Pharmacy, Ottawa Hospital General Campus, Ottawa, and ²Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, and Departments of Medicine and Microbiology, Health Sciences Centre, Winnipeg, Canada

With the expanded use of fluoroquinolones for the treatment of community-acquired respiratory infections and reports of tendon injury linked to the use of these agents, we reviewed the literature to investigate the frequency and strength of this association. Ninety-eight case reports were available for review. The incidence of tendon injury associated with fluoroquinolone use is low in a healthy population but increases in patients who have renal dysfunction, who are undergoing hemodialysis, or who have received renal transplants. Pefloxacin and ciprofloxacin were most frequently implicated, but tendon injury was reported with most fluoroquinolones. The median duration of fluoroquinolone treatment before the onset of tendon injury was 8 days, although symptoms occurred as early as 2 hours after the first dose and as late as 6 months after treatment was stopped. Up to one-half of patients experienced tendon rupture, and almost one-third received long-term corticosteroid therapy. Tendon injury associated with fluoroquinolone use is significant, and risk factors such as renal disease or concurrent corticosteroid use must be considered when these agents are prescribed.

The fluoroquinolone antimicrobials were first introduced in the 1980s and have since been used extensively to treat infections due to gram-negative organisms [1]. Recently, their use has expanded with the introduction of the “newer-generation” agents with improved activity against gram-positive and/or anaerobic bacteria [2]. These newer agents are now recommended for treatment of community-acquired pneumonia and acute exacerbations of chronic bronchitis [3, 4]. In the Canadian guidelines for community-acquired pneumonia, fluoroquinolones used for respiratory conditions, such as gatifloxacin, levofloxacin, and moxifloxacin, are recommended as first-line therapy for patients who have received antibiotics or oral corticosteroids within the past 3 months [3]. However, reports in the literature

about an association between the use of fluoroquinolones and oral corticosteroids and a possible increased incidence of tendon injuries are of concern. Therefore, a review of the literature was done to assess and describe any association found between the use of fluoroquinolones and the occurrence of tendon injury.

METHODS

The MEDLINE database was searched for available reports of fluoroquinolone-associated tendon injury published during 1966–2001, and all appropriate reports were gathered. All references were reviewed and all English- and French-language articles were included. English translations of abstracts from reports published in other languages were also included.

RESULTS

A total of 98 cases [5–40] were evaluated, as were a number of retrospective surveillance studies [41–44]. The first case report was published in 1983 [31]. Compiled results of 60 cases with available individualized data are described in table 1 [5–35]. Data include the

Received 29 November 2002; accepted 6 February 2003; electronically published 20 May 2003.

Reprints or correspondence: Dr. George G. Zhanel, Dept. of Microbiology, Health Sciences Centre, MS673, 820 Sherbrook St., Winnipeg, Manitoba R3A 1R9 Canada (ggzhanel@pcs.mb.ca).

Clinical Infectious Diseases 2003;36:1404–10

© 2003 by the Infectious Diseases Society of America. All rights reserved.
1058-4838/2003/3611-0008\$15.00

implicated fluoroquinolone, dose and duration of therapy when the tendon injury occurred, the tendon involved, time to onset of injury, the intervention(s) taken, time to recovery, and potential predisposing factors. The following text summarizes these 60 cases presented in table 1 and, when available, includes details from grouped data from case series [36–40], for a denominator of 98 cases. A comparison with the retrospective studies is presented in the discussion.

Fluoroquinolone implicated and duration of treatment.

Thirty-six (37%) of the 98 cases of fluoroquinolone-induced tendon injury were reported in association with pefloxacin. The majority of cases occurred with a pefloxacin dosage of 800 mg per day, although 1 patient reported receipt of 400 mg per day. The mean (\pm SD) duration of therapy was 18.2 ± 24.5 days, whereas the median duration was only 9 days. The second-most commonly implicated fluoroquinolone was ciprofloxacin (25.5% of all cases), with total daily doses ranging from 500 mg to 2000 mg, for a mean duration (\pm SD) of 24 ± 29.3 days (median, 7 days). Eleven cases (11.2%) were reported in association with norfloxacin (800 mg q.d.) when taken for 2–31 days total, 8 cases (8.2%) were reported in association with levofloxacin (8.2%), and 6 cases (6.1%) were reported in association with ofloxacin at 400 mg per day for 2–15 days. Five cases involving fleroxacin and 1 case involving enoxacin were also reported. Strictly speaking, enoxacin is not a fluoroquinolone, but it was included in this review.

Type of tendon injury and onset. The Achilles tendon was the most common site of injury (88 [89.8%] of 98 cases). Thirty-nine cases (44.3%) were bilateral. Other sites included the triceps epicondyle (2 cases), flexor tendon sheath (finger; 2 cases), thumb (3 cases), patellar (1 case), supraspinal tendon (1 case), quadriceps (1 case), subscapularis terrea (1 case), and rotator cuff (1 case) [6, 20, 29–33, 40]. Eighty-two patients (83.7%) experienced tendinitis. The mean time of onset of symptoms (\pm SD) after the initiation of fluoroquinolone therapy was 17.6 ± 19.5 days; however, 50% of cases occurred within 6 days. Tendon rupture occurred in 40 subjects (40.8%), with a mean onset (\pm SD) of 25.6 ± 42.3 days (median, 6 days) after the initiation of fluoroquinolone treatment. Tendon injury was reported to occur as early as 2 h after receipt of the first dose of a fluoroquinolone (ciprofloxacin) [26] to as late as 6 months after treatment had been terminated [20].

Clinical aspects of tendon injury. Tendon injury manifested most commonly with pain that was severe and of sudden onset. Other frequent signs and symptoms included tenderness to palpation, edema, and difficulty with movement of the involved area [11, 27, 31, 45]. Painful nodules, thickened tendon sheaths, warmth, stiffness, and erythema were also reported. Diagnoses were made primarily by physical examination, although occasionally radiography, ultrasonography, nuclear scanning, or MRI was used.

Interventions included discontinuation of the implicated fluoroquinolone in the majority of cases, as well as nonsurgical intervention (analgesics, physical therapy, heel raise, cast, or immobilization). Surgery was described in 9 cases (table 1). In 1 case, symptoms were alleviated with a reduction in the dosage of the fluoroquinolone (norfloxacin) from 400 mg twice per day to 200 mg per day [31]. Rechallenge at the higher dosage resulted in recurrence; however, once the dosage of 200 mg per day was reinstated, treatment was successfully continued. In another case, treatment with ciprofloxacin for 7 days resulted in improvement when instituted 2 weeks after a course of pefloxacin that was associated with tendon injury [11]. In 47 cases, treatment was not described. Recovery occurred in a mean (\pm SD) of 59.2 ± 101.2 days (median, 38.5 days; range, 2–600 days) with several reports describing recovery as “prolonged.” Sequelae were reported in 10 cases (10.2%) and included swelling, bruising, difficulty walking, decreased flexion, and pain.

Patient demographics and risk factors. The mean age (\pm SD) was 59.0 ± 16.0 years (range, 28–92 years). The ratio of men to women was 1.9:1. A small trend indicated that more men experienced injury in a tendon other than the Achilles, whereas more women experienced rupture of the involved tendon. These sex differences were small and were not observed in any other outcome measurement. Thirty-two (32.7%) of 98 patients were reported to have received systemic or inhaled (minimum of 4 cases inhaled) corticosteroids before and during fluoroquinolone administration; in most cases, treatment with steroids was long-term. Twenty-one (52.5%) of the 40 patients with tendon rupture received corticosteroids. The occurrence of other risk factors that have been suggested to play a role include hemodialysis or renal dysfunction (14 cases), renal transplantation (12 cases), rheumatic disease (9 cases), gout (2 cases), diabetes mellitus (2 cases), hyperparathyroidism (3 cases), participation in sports (2 cases), and hypothyroidism (1 case).

DISCUSSION

The results of this review suggest that male patients with a mean age of ~59 years are more likely to experience tendon injuries when receiving fluoroquinolones, although women are still susceptible, and age of affected persons had a range of 28–92 years. The preponderance of Achilles tendon injuries in boys and men has been noted in the sports medicine literature [46]. In our data set, we also noted a more frequent occurrence among men, although we found only 2 reports that involved sports-related injuries. The drugs most commonly implicated were pefloxacin and ciprofloxacin. The majority of injuries occurred in the Achilles tendon, and rupture is described in almost one-half of the reports described. Although the onset of symptoms typically occurs within 1–2 weeks, injury was also

Table 1. Clinical characteristics of patients with fluoroquinolone-associated tendinopathy.

Patient	Age in years, sex	Drug	Dose	Duration, days	Indication	Tendon	Tendonitis	U/B	Rupture	Steroids	Time to onset	Diagnosis	Duration of recovery, weeks	Intervention	Sequelae ^a	Country	Reference
1	74, F	Pfx	800 mg q.d.	15	Respiratory	Achilles	Yes	B	No	Yes	15 days	Clinical	6	Rest	No	France	[5]
2	69, F	Pfx	800 mg q.d.	2	Respiratory	Achilles	Yes	U	No	Yes	15 days	Clinical	1	Rest	No	France	[5]
3	34, F	Pfx	800 mg q.d.	90	Osteomyelitis	Achilles	Yes	U	No	No	70 days	US	4	Rest	No	France	[5]
4	48, M	Pfx	800 mg q.d.	4	Orciitis	Epicondyle (elbow)	Yes	U	No	No	2 days	Clinical	1.5	Surgery	Yes	France	[6]
5	61, M	Pfx	800 mg q.d.	10	Prostatitis	Achilles	Yes	B	No	No	4 days	Radiographic	8	Discontinued drug	No	France	[7]
6	58, M	Pfx	800 mg q.d.	42	Prostatitis	Achilles	Yes	B	No	No	30 days	Radiographic	<1	Discontinued drug	No	France	[7]
7	49, M	Pfx	800 mg q.d.	2	Urinary	Achilles	Yes	U	Yes	No	1 days	Clinical	6	Immobilization	No	France	[8]
8	75, M	Pfx	800 mg q.d.	2	Surgical prophylaxis	Achilles	Yes	U	No	No	1 days	Clinical	3	Rest	No	France	[8]
9	68, M	Pfx	800 mg q.d.	49	Spondylitis	Achilles	Yes	B	Yes	No	60 days	Clinical	8	Surgery	No	France	[8]
10	70, M	Pfx	800 mg q.d.	8	Respiratory	Achilles	Yes	U	No	No	5 days	Clinical	4	Immobilization	No	France	[8]
11	68, M	Pfx	800 mg q.d.	>90	spondylodiskitis	Achilles	Yes	B	Yes	No	53 days	Nuclear, radiographic	4	NA	Yes	France	[9]
12	54, M	Pfx	800 mg q.d.	7	Prostatitis	Achilles	Yes	B	No	NA	6 days	NA	80	Surgery	No	France	[10]
13	64, M	Pfx	800 mg q.d.	NA	Urinary	Achilles	Yes	U	No	NA	5 days	Clinical	NA	Discontinued drug	Yes (1 year)	Holland	[11]
14	76, M	Pfx	800 mg q.d.	NA	Respiratory	Achilles	Yes	B	No	Yes ^b	6 days	Clinical	2	7 days of Cptx 2 weeks after Pfx	No	Holland	[11]
15	33, M	Pfx	800 mg q.d.	10	Prostatitis	Achilles	Yes	U	No	NA	NA	Clinical	1.5	Discontinued drug	No	Holland	[11]
16	64, M	Pfx	800 mg q.d.	NA	Urinary	Achilles	Yes	B	No	NA	NA	Clinical	NA	Discontinued drug	No	Holland	[11]
17	65, F	Pfx	800 mg q.d.	NA	NA	Achilles	Yes	U	No	NA	10 days	NA	NA	NA	No	France	[12]
18	77, M	Pfx	800 mg q.d.	NA	NA	Achilles	Yes	B	No	NA	5 days	NA	2	NA	No	France	[12]
19	68, M	Pfx	800 mg q.d.	9	Respiratory	Achilles	Yes	B	Yes	NA	5 days	US	NA	Cast	No	France	[13]
20	64, NA	Pfx	800 mg q.d.	21	Sepsis	Achilles	Yes	B	Yes	NA	15 days	US	NA	Surgery	Yes	France	[13]
21	40, F	Pfx	400 mg q.d.	2	Urinary	Achilles	Yes	B	Yes	Yes	No	Clinical	12	Immobilization	No	France	[8]
22	64, M	Pfx	NA	NA	NA	Achilles	Yes	NA	NA	NA	NA	NA	NA	NA	No	Holland	[14]
23	64, M	Pfx	NA	NA	NA	Achilles	Yes	NA	NA	NA	NA	NA	NA	NA	No	Holland	[14]
24	33, M	Pfx	NA	NA	NA	Achilles	Yes	NA	NA	NA	NA	NA	NA	NA	No	Holland	[14]
25	76, M	Pfx	NA	NA	NA	Achilles	Yes	NA	NA	NA	NA	NA	NA	NA	No	Holland	[14]
26	60, F	Cpfx	1000 mg b.i.d. ^c	56	Osteoarthritis	Achilles	Yes	B	Yes	No	56 days	MRI	32	Cast, heel raise	Yes	UK	[15]
27	33, M	Cpfx	750 mg b.i.d. ^c	84	Osteomyelitis	Achilles	Yes	B	No	No	42 days	MRI	14	Rest	No	Sweden	[16]
28	70, F	Cpfx	750 mg b.i.d.	7	Respiratory	Achilles	No	B	Yes	Yes	5 days	Clinical	No	Surgery, rehabilitation	No	Australia	[17]
29	65, F	Cpfx	750 mg b.i.d.	6	Respiratory	Achilles	Yes	B	Yes	Yes	5 days	Clinical	>6	Plaster	Yes	New Zealand	[18]
30	67, M	Cpfx	750 mg b.i.d.	7	Respiratory	Achilles	Yes	B	No	Yes ^b	3 days	Clinical	6	NSAIDs	No	UK	[19]
31	49, M	Cpfx	500 mg b.i.d.	7	Surgical prophylaxis	Achilles	Yes	U	No	No	14 days	US	36	Rest	Yes	Sweden	[16]
32	38, M	Cpfx	500 mg b.i.d.	7	Respiratory	Achilles	No	U	Yes	No	180 days After ^d	Clinical	NA	Surgery	No	USA	[20]
33	73, F	Cpfx	500 mg b.i.d.	5	Gastroenteritis	Achilles	Yes	U	No	No	3 days	Clinical	<1	Rest, discontinued drug	No	Spain	[21]
34	40, M	Cpfx	500 mg b.i.d.	No	Prostatitis	Achilles	Yes	B	No	NA	After ^d	NA	6	NA	No	Israel	[22]
35	33, M	Cpfx	500 mg b.i.d.	4	Peritonitis	Achilles	Yes	B	Yes	NA	4 days	Clinical	NA	Cast	No	New Zealand	[23]

36	45, F	Cpfx	500 mg b.i.d.	8	Fever of unknown origin	Achilles	Yes	U	Yes	No	10 days after ^d	Radiographic	8	Rest, cast	No	France	[24]
37	54, M	Cpfx	500 mg b.i.d.	70	Prostatitis	Subscapularis	Yes	U	No	No	60 days	MRI	5	Discontinued drug, NSAID, rehabilitation	No	USA	[20]
38	39, NA	Cpfx	500 mg b.i.d.	>14	Gastroenteritis	Achilles	Yes	NA	No	NA	14 days	NA	<1	Rest	No	Spain	[25]
39	33, NA	Cpfx	500 mg b.i.d.	>14	Gastroenteritis	Achilles	Yes	NA	No	NA	14 days	NA	<1	Rest	No	Spain	[25]
40	81, F	Cpfx	1000 mg q.d.	NA	No	Achilles	Yes	U	No	NA	9 days	NA	8	NA	No	France	[12]
41	45, M	Cpfx	800 mg q.d.	NA	Respiratory	Epicondyle (elbow)	Yes	U	No	No	3 days	US, MRI	NA	Cast, surgery	No	France	[6]
42	66, M	Cpfx	250 mg b.i.d.	1	Respiratory	Achilles	Yes	U	Yes	Yes	2 h after first dose	Clinical	NA	NA	No	New Zealand	[26]
43	28, F	Cpfx	NA	14	Sinusitis	Achilles	Yes	U	No	No	17 days after ^d	Clinical	6	NSAID, rest	No	USA	[27]
44	45, F	Cpfx	NA	NA	No	Achilles	No	U	Yes	No	30 days	MRI	NA	Surgery	No	Germany	[28]
45	37, M	Cpfx	NA	60	No	Quadriceps	No	NA	Yes	No	60 days	NA	NA	NA	No	Switzerland	[29]
46	68, M	Cpfx	NA	NA	No	Achilles	Yes	B	No	Yes	2 days	NA	4	Discontinued drug	No	Switzerland	[29]
47	75, M	Nfx	800 mg q.d.	2–6	Urinary	Achilles	Yes	B	Yes	Yes	2 days	US	>3	Rest, heelpiece	Yes	France	[5]
48	68, M	Nfx	800 mg q.d. ^e	6	Prostatitis	Achilles	Yes	B	No	No	6 days	Clinical	<1	Bed rest, discontinued drug	No	France	[5]
49	78, NA	Nfx	800 mg q.d.	NA	Urinary	Achilles	Yes	B	Yes	Yes	Hours	NA	NA	Discontinued drug	No	France	[30]
50	67, NA	Nfx	800 mg q.d.	NA	Urinary	Long extensor of thumb	No	NA	Yes	No	4 days	NA	NA	Surgery	No	France	[30]
51	56, M	Nfx	400 mg b.i.d.	NA	Urinary	Achilles	Yes	B	No	NA	13 days	Clinical	3	Resolved with decreased dose	No	New Zealand	[31]
52	34, M	Nfx	400 mg b.i.d.	31	Urinary	Flexor tendon sheath (finger)	Yes	B	No	NA	Hours	Clinical	<1	Discontinued drug	No	New Zealand	[31]
53	92, F	Ofx	400 mg q.d.	2	Respiratory	Achilles	Yes	B	Yes	No	2 days	US, MRI	>6	Cast, discontinued drug	Yes	France	[5]
54	86, F	Ofx	400 mg q.d.	8	Urinary	Achilles	Yes	U	No	No	3 days	Clinical	8	Rest	No	France	[8]
55	67, M	Ofx	400 mg q.d.	15	Respiratory	Achilles	Yes	B	No	Yes	8 days	Clinical	8	Rest	No	France	[8]
56	73, F	Ofx	NA	NA	Sepsis	Rotator cuff	No	NA	Yes	NA	NA	NA	NA	NA	No	France	[32]
57	53, F	Ofx	NA	8	Respiratory	Achilles; finger, thumb, supraplinal muscle	Yes	B	No	Yes ^b	14 days after ^d	Clinical	8	Acetaminophen	No	France	[33]
58	55, M	Fix	NA	NA	NA	Thumb	Yes	B	No	Yes	2 days	NA	4	Discontinued drug	No	Switzerland	[29]
59	85, M	Enx	400 mg b.i.d.	>7	Urinary	Achilles	Yes	B	Yes	Yes	7 days	MRI	NA	Brace	No	USA	[34]
60	83, F	Lev	500 mg q.d.	10	Respiratory	Achilles	Yes	B	No	No	3 days	Clinical	10	Immobilization, walker	Yes	USA	[35]

NOTE. B, bilateral; Cpfx, ciprofloxacin; Enx, enoxacin; Fix, feroxacin; Lev, levofloxacin; NA, information not available; Nfx, norfloxacin; Ofx, ofloxacin; Pfx, pefloxacin; post, onset occurred after drug was discontinued; U, unilateral; UK, United Kingdom; US, ultrasonographic; USA, United States.

^a Sequelae included swelling, bruising, difficulty walking, decreased flexion, and pain.

^b Inhaled.

^c Dose reduced to 500 mg b.i.d. for 8 weeks after 4 weeks at initial dose.

^d Time after treatment terminated.

^e Therapy interrupted for treatment with iv Pfx, 800 mg daily, for 4 days.

described within hours to as long as months after the initiation of treatment and even after discontinuation. Recovery took 1–2 months, requiring rest and immobilization, with a small percentage of patients undergoing surgery. Use of corticosteroids was documented for 32.7% of the patients reviewed, suggesting a possible predisposition. Another 3 patients, who were renal transplant recipients [23, 31], also likely received high-dose corticosteroid therapy.

The incidence of fluoroquinolone-induced tendon injury in an otherwise healthy population is not well established, but reports suggest that it is low, ranging from 0.14% to 0.4% [41, 43, 47]. However, a number of factors have been suggested to further predispose a patient to such injury. In the renal transplant population, an incidence of 12.2%–15.6% is reported, compared with 0.6%–3.6% for transplant recipients not receiving fluoroquinolones [44, 48]. It is possible that this is because of reduced drug clearance. It has generally been agreed that advanced age is also a predisposing factor for this injury. Other proposed factors include renal failure and/or hemodialysis, diabetes mellitus, hyperparathyroidism, rheumatic disease, gout, participation in sports, and use of corticosteroids [5, 6, 29, 31, 48]. Similar to transplant recipients, patients receiving corticosteroids appear to be predisposed to tendon injury [49]; the addition of a fluoroquinolone potentially creates additive or synergistic toxicity.

In France, Pierfitte and Royer [42] reported the largest review of patients with tendon injuries and the potential association with fluoroquinolones. Four hundred twenty-one cases were reviewed from pharmacovigilance and pharmaceutical manufacturer databases. Similar to our findings, the most commonly implicated agent was pefloxacin, to which 68% of cases were attributed. Eighteen percent of cases were attributed to ofloxacin, 8% were attributed to norfloxacin, and only 5% were attributed to ciprofloxacin; the distribution was likely a reflection of local prescribing habits. The mean duration of treatment was 13 days. Ninety-eight percent of cases occurred in the Achilles tendon. Three occurred in the rotator cuff, 2 occurred in the quadriceps femoris tendon, and 1 occurred in the biceps. Fifty percent were bilateral. The mean time to onset was earlier than in our review (9.3 days), with a similar range of 1–152 days. Recovery was reported to occur primarily in 15–30 days, although a duration of as long as 2 months was also reported, and sequelae occurred in 3%–10% of cases. This contrasts with our review, in which the mean duration of recovery was 59.2 days (median, 38.5 days). We also found that recovery could take as long 20 months, with sequelae reported in 10% of cases (table 1). The mean age was 62 years in the report by Pierfitte and Royer [42], and the ratio of male to female patients was 1.3:1. Risk factors were not discussed in detail, although corticosteroid use was reported for 10% of patients with tendinitis and for 30% of those with rupture [42].

Three other studies described comparisons of patients who had received fluoroquinolones with those who had not been treated in an attempt to quantify incidence and association with these agents as well as with corticosteroid therapy. A more recent retrospective study [43] reported results that were collected from an outpatient database in The Netherlands. In that study, 1841 patients who had received a fluoroquinolone were compared with 9406 patients who had received another class of antimicrobials (amoxicillin, trimethoprim, trimethoprim-sulfamethoxazole, or nitrofurantoin) to determine the association, incidence, and relative risk of using a fluoroquinolone and developing tendinopathies. Patients were excluded if they had a history of tendon injury, prior trauma, or inadequate diagnosis and if they had rheumatic disease, systemic lupus erythematosus, gout, polymyositis, Reiter syndrome, or AIDS. Of a total of 97 tendinopathies, only 22 were included: 7 that occurred with fluoroquinolone use and 15 that occurred with use of other antimicrobials during total exposure periods of 19,751 and 458,484 days, respectively. This resulted in incidences of 7.74 cases per 100,000 days for fluoroquinolones and 3.27 cases per 100,000 days for the other antimicrobials, or a relative risk of 2.4. Ofloxacin was shown to have a relative risk of 4.9. These risks adjusted to 3.7 for all fluoroquinolones and 10.1 for ofloxacin when the incidence of Achilles tendinopathies was evaluated specifically. No association was found with ciprofloxacin or norfloxacin. An association was also not found for corticosteroids.

An earlier retrospective review of 230 renal transplant recipients was done to determine whether the addition of a fluoroquinolone would increase the risk of tendinopathies in a population receiving treatment with high-dose corticosteroids [44]. Patients who underwent transplantation during the period of January 1991 through December 1992 were included. An association was defined as the occurrence of tendinopathy during or \leq 15 days after discontinuation after fluoroquinolone therapy. Ninety fluoroquinolone-treated patients were compared with 140 untreated patients. No significant difference was described between the groups with respect to transplant mismatches, duration of hemodialysis, presence of diabetes, or serum creatinine levels. The fluoroquinolone group had a slightly higher mean age (50.4 vs. 46.6 years). In the treated group, 11 patients (12.2%) experienced tendinopathies, compared with 5 (3.6%) in the untreated group. Ten of the 11 treated patients received pefloxacin; 1 received its metabolite, norfloxacin. No patient who received ciprofloxacin or ofloxacin experienced tendinopathy. Of the patients who experienced tendinopathies, the fluoroquinolone-treated patients were found to have been undergoing hemodialysis for a significantly longer duration (mean duration of hemodialysis, 61.5 vs. 36.4 months). No association was found between the groups with

respect to daily corticosteroid dose, duration of therapy, or number of steroid-treated acute rejections.

A brief report describing a retrospective review of renal transplant recipients supports the findings that corticosteroid dose does not affect outcome [48]. Of a total of 340 patients, 32 of whom were treated with fluoroquinolones, no difference was described with regard to duration of dialysis, degree of hyperparathyroidism, serum calcium or phosphate levels, or dose of corticosteroids. Age, however, was found to be higher for patients with tendinopathies in the treated group.

Mechanism of injury. Injuries to the Achilles tendon involving sports may be classified into various categories, varying from focal lesions to peritendonitis to rupture [50]. Pathological changes may be minimal or nonexistent in tendinitis with edema; or they may be degenerative focal disease, with granulomatous changes and capillary cell proliferation; or they may display infiltration of fibrocytes, as in chronic tendinitis [50]. Hyaline and mucoid degeneration, chondroid metaplasia of the tenocytes, and alterations in mucopolysaccharide and collagen fibers are also described. Narrowed vasculature of the tendon and paratendon suggest that changes in blood flow may play a role [46]. The low supply of blood to the tendons, particularly the Achilles, which is further decreased with age, likely predisposes to injury [46]. Degenerative changes are not thought to predispose to rupture specifically [50]. High-impact use of the Achilles tendon leads to the site being the most common for injury; however, other sites are not excluded [6].

The mechanism by which fluoroquinolones are thought to cause tendon injury has not been established, although a number of suggestions have been made. Jorgensen et al. [9] described the pathological findings for a 68-year-old man who had been treated for 3 months with pefloxacin as demonstrating degenerative lesions, fissures, interstitial edema without cellular infiltration, necrosis, and neovascularization. Beuchard et al. [10] described a 54-year-old man who had received pefloxacin therapy for only 1 week and who had normal tendon tissue without degenerative lesions, thickening of the vasculature, hyaline deposits, and inflammatory infiltrate. It was suggested that an ischemic vascular process was the cause in these patients. Necrosis has also been noted in other patients who have received norfloxacin and ciprofloxacin [20, 28]. Le Huec et al. [6] suggested that the mechanism may be related to direct toxicity to the collagen because of the rapid onset of tendon injury [6]. In renal transplant recipients, it is possible that the reduced clearance of the fluoroquinolone results in elevated concentrations that might play a role in toxicity as the incidence increases in this population.

Animal studies. The use of pefloxacin in a mouse model demonstrated a change in proteoglycan synthesis in the Achilles tendon [51]. Oxidative damage was also found, suggesting the involvement of a reactive oxygen species. The authors proposed

that age, sports activity, or corticosteroid therapy may play a role in preventing repair in the tendon. This could lead to irreversible matrix changes and rupture.

The toxic effects of various fluoroquinolones were evaluated in a juvenile rat model [52]. Edema and increased mononuclear cells were often found in the tendon sheath of the Achilles. Pefloxacin, fleroxacin, levofloxacin, and ofloxacin were found to induce the greatest number of lesions. Administration of enoxacin, norfloxacin, and ciprofloxacin had little or no effect. The authors suggested that the substituent at the seventh position of the fluoroquinolone molecule might play a role, because the agents with the highest toxicity all share a methylpiperadiny moiety at this position, whereas the other 3 have a piperadiny substituent. Nitric oxide and 5-lipoxygenase were also found to play a role. Another animal study described alterations in the viability of rabbit tenocytes by quinolones that are fluorinated but not by those that are not fluorinated [53]. Further studies are required to elucidate whether a structure-activity relationship exists.

In conclusion, pefloxacin and ciprofloxacin were the most frequently implicated agents, but tendon injury was reported in association with most fluoroquinolones. Overall, very few cases were from North America or continents other than Europe, which may be partly related to the fluoroquinolones implicated or available and/or to underreporting in other continents. Use of ciprofloxacin and levofloxacin is extensive in North America, and with the availability of other new fluoroquinolones, such as gatifloxacin and moxifloxacin, their use will only increase. Careful consideration should be given to the use of fluoroquinolones in combination with corticosteroids or to the use of fluoroquinolones for treating patients with renal dysfunction, because these groups are at high risk for fluoroquinolone-associated tendinopathy.

References

1. Zhanel GG, Walkty A, Vercaigne L, et al. Fluoroquinolones in Canada: a critical review. *Can J Infect Dis* **1999**; 10:207–38.
2. Zhanel GG, Ennis K, Vercaigne L, Gin AS, Embil J, Hoban DJ. Critical review of fluoroquinolones: focus on respiratory infections. *Drugs* **2002**; 62:13–59.
3. Mandell LA, Marrie TJ, Grossman RF, et al. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. *Clin Infect Dis* **2000**; 31:383–421.
4. Bartlett JG, Dowell SF, Mandell LA, et al. Practice guidelines for the management of community-acquired pneumonia in adults. *Clin Infect Dis* **2000**; 31:347–82.
5. Zabraniecki L, Negrier I, Vergne P, et al. Fluoroquinolone induced tendinopathy: report of 6 cases. *J Rheumatol* **1996**; 23:516–20.
6. Le Huec JC, Schaefferbeke T, Chauveaux, Rivel J, Dehais J, Le Rebeller A. Epicondylitis after treatment with fluoroquinolone antibiotics. *J Bone Joint Surg Br* **1995**; 77:293–5.
7. Blanche P, Sereni D, Sicard D, et al. Tendinopathies achilléennes induites par la péfloxacin: a propos de 2 cas. *Ann Med Interne (Paris)* **1992**; 143: 348.

8. Ribard P, Audisio F, Kahn MF, et al. Seven Achilles tendonitis including 3 complicated by rupture during fluoroquinolone therapy. *J Rheumatol* **1992**; 19:1479–81.
9. Jorgensen C, Anaya JM, Didry C, et al. Arthropathies et tendinopathie achilléenne induites par la péfloxacin. *Rev Rhum Mal Osteoartic* **1991**; 58:623–5.
10. Beuchard J, Rochcongar P, Saillant G, et al. Tendinopathie achilléenne bilatérale chronique à la péfloxacin, sans rupture spontanée, traitée chirurgicalement. *Presse Med* **1996**; 25:1083.
11. Meyboom RHB, Olsson S, Knol A, et al. Achilles tendonitis induced by pefloxacin and other fluoroquinolone derivatives. *Pharmacoepidemiology and Drug Safety* **1994**; 3:185–9.
12. Cohen de Lara A, Rosenberg F, Struz P. Trois nouveau cas de tendinopathie achilléenne après traitement par fluoroquinolones. *Rev Rhum Mal Osteoartic* **1992**; 59:652.
13. Franck JL, Bouteiller G, Chagnaud P, et al. Ruptures des tendons d'Achille chez deux adultes traités par péfloxacin d'ont un cas bilatéral. *Rev Rhum Mal Osteoartic* **1991**; 58:904.
14. Dekens-Konter JA, Knol A, Olsson S, et al. Tendonitis of the Achilles tendon caused by pefloxacin and other fluoroquinolone derivatives [in Dutch]. *Ned Tijdschr Geneesk* **1994**; 139:528–31.
15. Movin T, Gad A, Güntner P, Földhazy, Rolf C. Pathology of the Achilles tendon in association with ciprofloxacin treatment. *Foot Ankle Int* **1997**; 18:297–9.
16. McGarvey WC, Singh D, Trevino SG. Partial Achilles tendon ruptures associated with fluoroquinolone antibiotics: a case report and literature review. *Foot Ankle Int* **1996**; 17:496–8.
17. Poon CCH, Sundaram NA. Spontaneous bilateral Achilles tendon rupture associated with ciprofloxacin. *Med J Aust* **1997**; 166:665.
18. West MB, Gow P. Ciprofloxacin, bilateral Achilles tendonitis and unilateral tendon rupture—a case report. *N Z Med J* **1998**; 111:18–9.
19. McEwan SR, Davey PG. Ciprofloxacin and tenosynovitis. *Lancet* **1988**; 2:900.
20. Casparian JM, Luchi M, Moffat RE, et al. Quinolones and tendon ruptures. *South Med J* **2000**; 93:488–526.
21. Carrasco JM. Tendonitis associated with ciprofloxacin. *Ann Pharmacother* **1997**; 31:120.
22. Mirovsky Y, Pollack L, Arlazoroff A, et al. Ciprofloxacin-associated bilateral acute Achilles tendonitis [in Hebrew] [abstract]. *Harefuah* **1995**; 129:470–2.
23. Lee TW, Collins JF. Ciprofloxacin associated bilateral Achilles tendon rupture. *Aust N Z J Med* **1992**; 22:500.
24. Boulay I, Farge D, Haddad A, et al. Tendinopathie à la ciprofloxacin avec possibilité de rupture partielle du tendon d'Achille. *Ann Med Interne (Paris)* **1993**; 144:493–4.
25. Hernández MV, Peris P, Sierra J, et al. Tendinitis por fluoroquinolonas: descripción de dos pacientes. *Med Clin (Barc)* **1994**; 103:264–6.
26. Jagose JT, McGregor DR, Nind GR, Bailey RR. Achilles tendon rupture due to ciprofloxacin. *N Z Med J* **1996**; 109:471–2.
27. Harrell RM. Fluoroquinolone-induced tendinopathy: what do we know? *South Med J* **1999**; 92:622–5.
28. Petersen W, Laprell H. Insidious rupture of the Achilles tendon after ciprofloxacin-induced tendinopathy: a case report [in German] [abstract]. *Unfallchirurgie* **1998**; 101:731–4.
29. Cattaneo F, Serna M, Stoller R. Fluoroquinolone associated tendon rupture and bilateral tendinitis in a hemodialysis patient and two renal transplant recipients. *Kidney Int* **1990**; 50:1429.
30. Chaslerie A, Bannwarth B, Landreau JM, Yver L, Begaud B. Ruptures tendineuses et fluoro-quinolones: un effet indésirable de classe. *Rev Rhum Mal Osteoartic* **1992**; 59:297–8.
31. Bailey RR, Kirk JA, Peddie BA. Norfloxacin-induced rheumatic disease. *N Z Med J* **1983**; 96:590.
32. Tonolli-Serabian I, Mattei JP, Poet JL, et al. Rupture de al coiffe des rotateurs au cours d'un traitement par quinolone. *Collection de Pathologie Locomotrice* **1993**; 26:147–50.
33. Schwald N, Debray-Meignan S. Suspected role of ofloxacin in a case of arthralgia, myalgia, and multiple tendinopathy. *Rev Rhum Engl Ed* **1999**; 66:419–21.
34. Huston KA. Achilles tendonitis and tendon rupture due to fluoroquinolone antibiotics. *N Engl J Med* **1994**; 331:748.
35. Lewis JR, Gums JG, Dickensheets DL. Levofloxacin-induced bilateral Achilles tendonitis. *Ann Pharmacother* **1999**; 33:792–5.
36. Borderie P, Marcelli C, Leray H, et al. Ruptures spontanées du tendon d'Achille après transplantation rénale: rôle favorisant des fluoroquinolones [abstract E22]. *Rev Rhum* **1992**; 59:652.
37. Gabutti L, Stoller R, Marti HP. Fluoroquinolone as etiology of tendinopathy [in German] [abstract]. *Ther Umsch* **1998**; 55:558–61.
38. Gillet P, Blum A, Pierfitte C, et al. Fluoroquinolone-associated Achilles's tendonitis: MRI findings [abstract B128]. *Arthritis Rheum* **1993**; 36:5163.
39. Perrot S, Kaplan G, Ziza JM. 3 cas de tendinite Achilléenne sous péfloxacin d'ont deux avec rupture [in French] [letter]. *Rev Rhum Mal Osteoartic* **1992**; 59:162.
40. Fleisch F, Hartmann K, Kuhn M. Fluoroquinolone-induced tendinopathy: also occurring with levofloxacin. *Infection* **2000**; 28:256–7.
41. Wilton LV, Pearce GL, Mann RD. A comparison of ciprofloxacin, norfloxacin, ofloxacin, azithromycin, and cefixime examined by observational cohort studies. *Br J Clin Pharmacol* **1996**; 41:277–84.
42. Pierfitte C, Royer RJ. Tendon disorders with fluoroquinolones. *Therapie* **1996**; 51:419–20.
43. van der Linden PD, van der Lei J, Nab HW, Knol A, Stricker BHC. Achilles tendonitis associated with fluoroquinolones. *Br J Clin Pharmacol* **1999**; 48:433–7.
44. Donck JB, Segaert MF, Vanrenterghem YF. Fluoroquinolones and Achilles tendinopathy in renal transplant recipients. *Transplantation* **1994**; 58:736–7.
45. Royer RJ, Pierfitte C, Netter P. Features of tendon disorders with fluoroquinolones. *Therapie* **1994**; 49:75–6.
46. Waterston SW, Maffulli N, Ewen WB. Subcutaneous rupture of the Achilles tendon: basic science and some aspects of clinical practice. *Br J Sports Med* **1997**; 31:285–98.
47. Lafon M. Tendinopathies et fluoroquinolones. *Concours Med* **1993**; 115:819–25.
48. Leray H, Mourad G, Chong G, et al. Ruptures spontanées du tendon d'Achille après transplantation rénale: rôle des fluoroquinolones. *Presse Med* **1993**; 22:1834.
49. Price AE, Evans PM, Waugh TR. Bilateral simultaneous Achilles tendon ruptures: a case report and review of the literature. *Clin Orthop* **1986**; 213:249–50.
50. Williams JGP. Achilles tendon lesions in sport. *Sports Med* **1986**; 3:114–35.
51. Simonin MA, Gegout-Pottie P, Minn A, et al. Pefloxacin-induced Achilles tendon toxicity in rodents: biochemical changes in proteoglycan synthesis and oxidative damage to collagen. *Antimicrob Agents Chemother* **2000**; 44:867–72.
52. Kashida Y, Kato M. Characterization of fluoroquinolone-induced Achilles tendon toxicity in rats: comparison of toxicities of 10 fluoroquinolones and effects of anti-inflammatory compounds. *Antimicrob Agents Chemother* **1997**; 41:2389–93.
53. Kahn MF, Hayem G. Tendons and fluoroquinolones: unresolved issues. *Rev Rhum Engl Ed* **1997**; 64:437–9.